Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical ESBA105 in acute anterior uveitis (Phase 2, open-label)
2008-004862-24Phase 2Terminated
- Sponsor
- ESBATech
- Start
- Oct 2008
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DLX105 in cyclitis, sponsored by ESBATech. Primary endpoints: Safety and local tolerability and Clinical activity in anterior uveitis. Started Oct 2008; status: terminated.
02
Drugs
DLX105
03
Conditions
cyclitis
Beyond the preview
Go deeper on 2008-004862-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004862-24.